Compare Stocks: PTNT, MBIO, ONCO, and EVGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVGN Evogene	$0.43 -2.4%	$0.53	$0.35 ▼ $1.50	$3.71M	1.44	1.19 million shs	142,541 shs
MBIO Mustang Bio	$0.47 +0.8%	$0.55	$0.46 ▼ $1.85	$3.57M	2.09	109,887 shs	33,392 shs
ONCO Onconetix	$0.73 -1.4%	$0.79	$0.59 ▼ $209.50	$3.21M	2.61	1.24 million shs	391,264 shs
PTNT Palatin Technologies	$24.55 +1.4%	$24.48	$23.83 ▼ $28.06	$982K	1.64	824 shs	18 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVGN Evogene	+9.70%	+2.74%	-16.36%	+1.37%	-62.19%
MBIO Mustang Bio	+0.91%	-11.21%	-14.76%	-33.54%	-70.24%
ONCO Onconetix	-4.88%	-18.31%	+13.99%	-22.12%	-99.50%
PTNT Palatin Technologies	+0.91%	+0.08%	+0.70%	-6.22%	+336.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVGN Evogene	$0.43 -2.4%	$0.53	$0.35 ▼ $1.50	$3.71M	1.44	1.19 million shs	142,541 shs
MBIO Mustang Bio	$0.47 +0.8%	$0.55	$0.46 ▼ $1.85	$3.57M	2.09	109,887 shs	33,392 shs
ONCO Onconetix	$0.73 -1.4%	$0.79	$0.59 ▼ $209.50	$3.21M	2.61	1.24 million shs	391,264 shs
PTNT Palatin Technologies	$24.55 +1.4%	$24.48	$23.83 ▼ $28.06	$982K	1.64	824 shs	18 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVGN Evogene	+9.70%	+2.74%	-16.36%	+1.37%	-62.19%
MBIO Mustang Bio	+0.91%	-11.21%	-14.76%	-33.54%	-70.24%
ONCO Onconetix	-4.88%	-18.31%	+13.99%	-22.12%	-99.50%
PTNT Palatin Technologies	+0.91%	+0.08%	+0.70%	-6.22%	+336.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVGN Evogene	1.00	Sell	N/A	N/A
MBIO Mustang Bio	1.00	Sell	N/A	N/A
ONCO Onconetix	1.00	Sell	N/A	N/A
PTNT Palatin Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PTNT, MBIO, ONCO, and EVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/24/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
9/9/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/25/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/11/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	MBIO Mustang Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	ONCO Onconetix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/8/2026	EVGN Evogene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVGN Evogene	$3.85M	0.96	N/A	N/A	$1.37 per share	0.31
MBIO Mustang Bio	N/A	N/A	N/A	N/A	$1.31 per share	N/A
ONCO Onconetix	$810K	3.97	N/A	N/A	$505.29 per share	0.00
PTNT Palatin Technologies	$4.49M	0.22	N/A	N/A	($0.25) per share	-98.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVGN Evogene	-$8.48M	-$0.91	N/A	N/A	N/A	-694.18%	-156.53%	-86.80%	11/18/2026 (Estimated)
MBIO Mustang Bio	-$1.92M	-$0.45	N/A	N/A	N/A	N/A	-34.23%	-17.55%	11/18/2026 (Estimated)
ONCO Onconetix	-$14.03M	$248.12	0.00	N/A	N/A	-1,575.89%	-91.95%	-53.76%	11/12/2026 (Estimated)
PTNT Palatin Technologies	-$29.74M	-$60.00	N/A	N/A	N/A	N/A	N/A	-365.57%	N/A

Latest PTNT, MBIO, ONCO, and EVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	ONCO Onconetix	-$4,505.00	-$1.28	+$4,503.72	-$1.28	$0.02 million	$0.02 million
8/5/2026	Q2 2026	MBIO Mustang Bio	-$140.00	-$0.16	+$139.84	-$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVGN Evogene	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
ONCO Onconetix	N/A	N/A	N/A	N/A	N/A
PTNT Palatin Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVGN Evogene	N/A	3.57	3.54
MBIO Mustang Bio	N/A	1.97	1.97
ONCO Onconetix	N/A	2.21	2.14
PTNT Palatin Technologies	N/A	0.38	0.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVGN Evogene	10.40%
MBIO Mustang Bio	9.95%
ONCO Onconetix	23.89%
PTNT Palatin Technologies	11.50%

Insider Ownership

Company	Insider Ownership
EVGN Evogene	7.40%
MBIO Mustang Bio	4.00%
ONCO Onconetix	0.27%
PTNT Palatin Technologies	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVGN Evogene	52	8.72 million	8.07 million	No Data
MBIO Mustang Bio	4	7.58 million	7.27 million	Not Optionable
ONCO Onconetix	2	4.38 million	4.37 million	N/A
PTNT Palatin Technologies	30	40,000	18.16 million	Not Optionable

PTNT, MBIO, ONCO, and EVGN Headlines

Recent News About These Companies

Palatin Technologies (OTCMKTS:PTNT) Shares Cross Above 200-Day Moving Average - Time to Sell?

September 30 at 1:42 AM | americanbankingnews.com

Palatin Technologies (PTN): Fiscal 2026 Revenue Inflection Comes With a Liquidity Test

September 29 at 9:02 AM | news.alphastreet.comN

Palatin Targets the Next Generation of Rare Obesity Therapies After MC4R Validation (NASDAQ: PTN)

September 28, 2026 | markets.businessinsider.com

Palatin reveals $13.2 million fiscal 2026 revenue

September 28, 2026 | grafa.comG

Palatin Technologies (OTCMKTS:PTNT) Stock Passes Above 200 Day Moving Average - Time to Sell?

September 22, 2026 | americanbankingnews.com

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

July 22, 2026 | markets.businessinsider.com

Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters

June 18, 2026 | theglobeandmail.com

Palatin Technologies Voluntarily Transfers Stock Listing to Nasdaq

May 19, 2026 | theglobeandmail.com

Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange

May 19, 2026 | finanznachrichten.de

Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...

February 17, 2026 | finance.yahoo.com

Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

February 17, 2026 | finanznachrichten.de

Palatin Technologies Inc trading halted, volatility trading pause

November 21, 2025 | msn.com

Palatin Technologies, Inc. (AMEX:PTN) Q1 2026 Earnings Call Transcript

November 18, 2025 | msn.com

Palatin Technologies Inc (PTN) Q1 2026 Earnings Call Highlights: Strategic Collaborations and ...

November 14, 2025 | finance.yahoo.com

Palatin Technologies, Inc.: Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

November 13, 2025 | finanznachrichten.de

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

November 6, 2025 | finance.yahoo.com

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

September 22, 2025 | finance.yahoo.com

Nine new option listings and one option delisting on September 10th

September 10, 2025 | msn.com

Four new option listings and two option delistings on August 12th

August 14, 2025 | msn.com

Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

July 15, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PTNT, MBIO, ONCO, and EVGN Company Descriptions

Evogene NASDAQ:EVGN

$0.42 -0.01 (-2.43%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 -0.01 (-1.65%)

As of 05:03 PM Eastern

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Mustang Bio NASDAQ:MBIO

$0.47 +0.00 (+0.83%)

As of 03:59 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Onconetix NASDAQ:ONCO

$0.73 -0.01 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$0.73 0.00 (-0.64%)

As of 05:14 PM Eastern

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Palatin Technologies OTCMKTS:PTNT

$24.55 +0.35 (+1.45%)

As of 04:10 PM Eastern

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PTNT, MBIO, ONCO, and EVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PTNT, MBIO, ONCO, and EVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PTNT, MBIO, ONCO, and EVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PTNT, MBIO, ONCO, and EVGN Company Descriptions

Evogene NASDAQ:EVGN

Mustang Bio NASDAQ:MBIO

Onconetix NASDAQ:ONCO

Palatin Technologies OTCMKTS:PTNT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PTNT, MBIO, ONCO, and EVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PTNT, MBIO, ONCO, and EVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PTNT, MBIO, ONCO, and EVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PTNT, MBIO, ONCO, and EVGN Company Descriptions

Evogene NASDAQ:EVGN

Mustang Bio NASDAQ:MBIO

Onconetix NASDAQ:ONCO

Palatin Technologies OTCMKTS:PTNT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools